Evidence map›Paper›PMID 41244933›Full record

ArticleCardiovascular therapeutics2025

Effects of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors on Relationship Between B-Type Natriuretic Peptide and Hemoglobin Levels in Patients With Cardiorenal Anemia Syndrome.

Tomoaki Yoshitake, Toru Hashimoto, Shouji Matsushima, Kei Ikuta, Shoei Yamamoto, Tomoyasu Suenaga, Shunsuke Nakashima, Takashi Kai, Kayo Misumi, Keisuke Shinohara and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tomoaki YoshitakeDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Toru HashimotoDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-9607-0852
Shouji MatsushimaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-9774-4513
Kei IkutaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shoei YamamotoDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0009-0007-7740-6286
Tomoyasu SuenagaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shunsuke NakashimaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takashi KaiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kayo MisumiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0003-3441-1628
Keisuke ShinoharaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-3084-1711
Takeo FujinoDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-2886-3479
Shunsuke KatsukiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-7851-216X
Kazuya HosokawaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0003-1517-3660
Shintaro KinugawaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0003-2559-0054
Kohtaro AbeDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0003-4131-5423

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds: Anemia is associated with poor prognosis in heart failure patients. Erythropoiesis-stimulating agents have been used for the treatment of renal anemia, but they increase the risk of thrombotic events. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have emerged as a new treatment for renal anemia. HIF-PHIs are expected to have pleiotropic effects beyond correcting anemia. Evidence regarding the effects of HIF-PHIs in cardiorenal anemia syndrome has not been established. Methods and Results: The present study is a single-center, retrospective analysis of patients with heart failure and renal anemia who were treated with HIF-PHIs or oral iron supplementation at Kyushu University Hospital ( Conclusion: HIF-PHIs reduce BNP levels more than anticipated by the elevation of hemoglobin levels compared to oral iron supplementation. HIF-PHIs may have therapeutic benefits against heart failure beyond the correction of anemia in the heart failure patients.

Indexed as

AnemiaCardio-Renal SyndromeHeart FailureHematinicsHemoglobinsHypoxia-Inducible Factor-Proline DioxygenasesNatriuretic Peptide, BrainProlyl-Hydroxylase InhibitorsAgedAged, 80 and overBiomarkersFemaleHumansIronJapanMaleBiomarkersHematinicsHemoglobinsHypoxia-Inducible Factor-Proline DioxygenasesIronNatriuretic Peptide, BrainProlyl-Hydroxylase Inhibitorsanemiacardiorenal syndromechronic kidney diseaseheart failurehypoxia-inducible factor prolyl hydroxylase inhibitorsiron deficiency

Identifiers

PMID41244933
PMCPMC12615038

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.